 "AstraZeneca Pharma rallies post Q4 results")
AstraZeneca Pharma India has soared 17% to Rs 1,002 on the NSE in an otherwise weak market after the company reported a standalone net profit of Rs 38.13 crore in the fourth quarter ended March 31, 2015 (Q4) against a loss of Rs 2.57 crore in the year-ago quarter.
Total income from operations during the quarter under review increased by 48% to Rs 169 crore against Rs 114 crore in the corresponding quarter of previous year.
The company earned Rs 48 crore as service income pertaining to clinical trials and co-promotion activities during the quarter, AstraZeneca Pharma India said in a statement.
The stock hit a high of Rs 1,016 and has seen a combined 469,036 shares changing hands on the counter on the NSE and BSE so far.
At 1448 hours, the stock was up 15% to Rs 983 on the NSE.
Total income from operations during the quarter under review increased by 48% to Rs 169 crore against Rs 114 crore in the corresponding quarter of previous year.
The company earned Rs 48 crore as service income pertaining to clinical trials and co-promotion activities during the quarter, AstraZeneca Pharma India said in a statement.
The stock hit a high of Rs 1,016 and has seen a combined 469,036 shares changing hands on the counter on the NSE and BSE so far.
At 1448 hours, the stock was up 15% to Rs 983 on the NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%